ArticleNeuro-oncology advances

Phase I dose-escalation study of procaspase-activating compound-1 in combination with temozolomide in patients with recurrent high-grade astrocytomas.

Matthias Holdhoff et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.